AN4035

**AN4035** is a novel experimental **antibody-drug conjugate (ADC)** developed to target **CEACAM5**, a cell surface protein often overexpressed in various cancers. The ADC is "armed with a proprietary pan-RAS(ON) inhibitor payload," indicating its mechanism combines antibody-mediated targeting of CEACAM5-positive cells with delivery of an active agent that inhibits RAS proteins in their GTP-bound (ON) state. This dual mechanism aims to selectively destroy cancer cells expressing CEACAM5 while exploiting oncogenic RAS pathway dependence for enhanced anti-tumor efficacy. AN4035 is under clinical-stage development by Adlai Nortye, a company specializing in cancer immunotherapy and targeted therapies[1][4][7][10].